Israel Englander Autolus Therapeutics PLC Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Millennium Management LLC holds 862,804 shares of AUTL stock, worth $2.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

862,804

Previous 813,031 6.12%

Holding current value

$2.45 Million

Previous $2.83 Million 10.68%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.38 - $4.69 $168,232 - $233,435	49,773 Added 6.12%	862,804 $3.13 Million
Q2 2024 Aug 14, 2024	BUY	$3.33 - $5.68 $1.44 Million - $2.46 Million	432,503 Added 113.66%	813,031 $2.83 Million
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $1.72 Million - $2.33 Million	319,798 Added 526.59%	380,528 $2.43 Million
Q4 2023 Feb 14, 2024	BUY	$2.13 - $6.63 $129,354 - $402,639	60,730 New	60,730 $391,000
Q1 2023 May 15, 2023	BUY	$1.75 - $2.25 $410,366 - $527,613	234,495 Added 186.63%	360,145 $663,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $81,153 - $152,512	46,640 Added 59.03%	125,650 $239,000
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $323,643 - $596,520	-158,649 Reduced 66.75%	79,010 $169,000
Q2 2022 Aug 15, 2022	BUY	$2.04 - $4.68 $142,989 - $328,035	70,093 Added 41.83%	237,659 $673,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $502,508 - $779,458	-142,758 Reduced 46.0%	167,566 $699,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $678,845 - $931,749	-133,107 Reduced 30.02%	310,324 $1.61 Million
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $1.5 Million - $2.08 Million	-281,741 Reduced 38.85%	443,431 $2.9 Million
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $2.37 Million - $3.95 Million	496,663 Added 217.35%	725,172 $4.82 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $1.09 Million - $1.85 Million	197,636 Added 640.16%	228,509 $1.31 Million
Q4 2020 Feb 16, 2021	SELL	$8.13 - $12.79 $954,844 - $1.5 Million	-117,447 Reduced 79.18%	30,873 $276,000
Q3 2020 Nov 16, 2020	SELL	$11.64 - $16.3 $6.73 Million - $9.43 Million	-578,521 Reduced 79.59%	148,320 $1.73 Million
Q2 2020 Aug 14, 2020	SELL	$5.38 - $16.14 $303,017 - $909,053	-56,323 Reduced 7.19%	726,841 $11.7 Million
Q1 2020 May 14, 2020	BUY	$4.2 - $13.0 $448,068 - $1.39 Million	106,683 Added 15.77%	783,164 $4.69 Million
Q4 2019 Feb 14, 2020	SELL	$11.13 - $16.28 $8.01 Million - $11.7 Million	-719,661 Reduced 51.55%	676,481 $8.93 Million
Q3 2019 Nov 14, 2019	BUY	$9.79 - $16.72 $6.15 Million - $10.5 Million	628,306 Added 81.83%	1,396,142 $17.3 Million
Q2 2019 Aug 15, 2019	BUY	$15.1 - $31.25 $11.2 Million - $23.1 Million	740,639 Added 2723.24%	767,836 $12.4 Million
Q2 2019 Aug 14, 2019	SELL	$15.1 - $31.25 $6.39 Million - $13.2 Million	-423,165 Reduced 93.96%	27,197 $2.36 Million
Q1 2019 May 14, 2019	BUY	$24.38 - $34.71 $10.7 Million - $15.2 Million	438,662 Added 3749.25%	450,362 $14.2 Million
Q4 2018 Feb 14, 2019	SELL	$24.21 - $48.01 $587,286 - $1.16 Million	-24,258 Reduced 67.46%	11,700 $384,000
Q3 2018 Nov 14, 2018	SELL	$20.86 - $33.33 $2.29 Million - $3.67 Million	-109,987 Reduced 75.36%	35,958 $1.08 Million
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $3.65 Million - $4.05 Million	145,945 New	145,945 $3.91 Million

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $258M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account